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Background: Previous studies suggested that somatostatin given before endoscopic retrograde
cholangiopancreatography (ERCP) may reduce the incidence of post-ERCP pancreatitis. However, the
routine use of somatostatin in all patients undergoing ERCP is not likely to be cost effective. This study
evaluated whether intravenous bolus somatostatin given after diagnostic cholangiopancreatography could
reduce the incidence of pancreatitis in a group of patients undergoing therapeutic ERCP procedures.
Methods: In a randomised, double blind, controlled trial, the effect of intravenous bolus somatostatin
250 mg given immediately after diagnostic cholangiopancreatography was compared with that of placebo
in patients who required endoscopic sphincterotomy or other therapeutic procedures. The primary end
point was the incidence of post-ERCP clinical pancreatitis, and a secondary end point was the incidence of
hyperamylasemia.
Results: A total of 270 patients were randomised. The somatostatin group (n = 135) and the placebo group
(n = 135) were comparable in age, sex, indications for treatment, and types of procedure. The frequencies
of clinical pancreatitis (4.4% v 13.3%; p = 0.010) and hyperamylasemia (26.0% v 38.5%; p = 0.036) were
both significantly lower in the somatostatin group compared with the placebo group.
Conclusions: A single dose of intravenous bolus somatostatin, given immediately after diagnostic
cholangiopancreatography, is effective in reducing the incidence of pancreatitis after therapeutic ERCP.
This novel approach of administering prophylactic somatostatin may offer a cost effective prophylaxis for
post-ERCP pancreatitis.
A
cute pancreatitis is a common complication of endo-
scopic retrograde cholangiopancreatography (ERCP),
with an incidence of 8–18% in prospective studies.1–5
Several agents have been tested for their efficacy in
preventing post-ERCP pancreatitis. Somatostatin,6 7 octreo-
tide,8 9 and gabexate10 are the three most widely investigated
agents. A recent meta-analysis of randomised controlled
trials showed that somatostatin and gabexate, but not
octreotide, significantly reduced the incidence of post-ERCP
pancreatitis.11 The study also found that somatostatin was
more cost effective than gabexate from a pharmacoeconomic
point of view as the number of patients that need to be
treated to prevent one single episode of acute pancreatitis
was 13 for somatostatin and 27 for gabexate. However, the
study concluded that generalised treatment for all patients
undergoing ERCP is unlikely to be cost effective and
suggested that prophylactic therapy should be reserved for
high risk patients who will benefit most from the treatment.11
Somatostatin can be administered as a continuous infusion
or bolus intravenous injection before ERCP. A previous study
from our institution demonstrated that somatostatin infusion
started 30 minutes before ERCP and continued for 12 hours
after the procedure reduced the incidence of post-ERCP
pancreatitis.6 Most other studies on the effect of somatostatin
on post-ERCP pancreatitis also employed intravenous infu-
sion for 4–26 hours.12–14 However, continuous infusion
increases the cost of the treatment and is impractical for
ERCP as an outpatient procedure.11 15 16 In a recent study, a
single bolus intravenous injection of somatostatin just before
cannulation of the papilla significantly reduced the incidence
of post-ERCP pancreatitis, especially in patients undergoing
endoscopic sphincterotomy.7 This is a simpler and more cost
effective way of administering somatostatin, and it may be
useful in the outpatient setting. However, the generalised use
of prophylactic somatostatin in a large number of patients to
prevent a small number of cases of post-ERCP pancreatitis is
still not justified in terms of cost effectiveness. Most cases of
post-ERCP pancreatitis are mild and the main consequence is
prolonged hospital stay.6
Ideally, somatostatin should be used only in patients with
a high risk of post-ERCP pancreatitis to maximise the
benefit-cost ratio. Previous studies have identified sphincter
of Oddi dysfunction, non-dilated bile duct, difficult cannula-
tion, repeated pancreatic duct injection, pancreatic duct
acinarisation, endoscopic sphincterotomy, and therapeutic
procedures as risk factors for post-ERCP pancreatitis.2 17–21
Although patient factors such as sphincter of Oddi dysfunc-
tion and non-dilated bile duct may be known before ERCP,
technical factors are largely unpredictable before the proce-
dure. Even for patients who are likely to require a thera-
peutic procedure, the decision of whether to proceed to
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: CBD, common bile duct; ERCP, endoscopic retrograde
cholangiopancreatography
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sphincterotomy or other therapeutic procedures is made only
after successful cannulation and assessment of findings at
diagnostic cholangiopancreatography. Hence except for a few
cases with well defined risk factors, selective use of
prophylactic somatostatin in high risk patients before
cannulation is not practical in most circumstances.
The benefit of prophylactic somatostatin would be more
pronounced if a bolus injection during the procedure
immediately after diagnostic cholangiopancreatography
could reduce the risk of pancreatitis associated with
sphincterotomy or other therapeutic procedures, as dictated
by the findings of cholangiopancreatography. To test this
hypothesis, we conducted a randomised controlled trial to
evaluate the efficacy of bolus intravenous somatostatin given
immediately after diagnostic cholangiopancreatography in
reducing the incidence of pancreatitis in patients who
required sphincterotomy or other therapeutic procedures.
PATIENTS AND METHODS
Eligibili ty
A randomised, double blind, controlled trial was conducted
in the Endoscopy Unit of the Department of Surgery,
University of Hong Kong, Queen Mary Hospital, Hong
Kong. Eligible patients were those undergoing a first
therapeutic ERCP, with sphincterotomy or other therapeutic
procedures deemed necessary after a diagnostic cholangio-
pancreatography. Exclusion criteria included: (1) age
,18 years; (2) pregnancy; (3) previous sphincterotomy or
therapeutic ERCP; (4) acute myocardial infarction within
three months; (5) acute pancreatitis or hyperamylasemia at
the baseline blood test; (6) chronic pancreatitis; and (7)
history of allergic reaction to somatostatin. Informed consent
was obtained from all patients who participated in the study,
which was approved by the local ethics committee.
Study design
Before undergoing ERCP, all patients were fasted for six
hours. One dose of intravenous prophylactic antibiotic
(amoxicillin-clavulanic acid 1.2 g) was given before the
procedure and intravenous sedation was provided using
meperidine and midazolam. All procedures were performed
by fully trained endoscopists experienced in therapeutic
ERCP.
All patients underwent a diagnostic cholangiopancreato-
graphy first. For patients with suspected biliary disease,
selective cannulation of the common bile duct (CBD) was
attempted without cannulation or injection of the pancreatic
duct whenever possible. Pancreatic duct cannulation or
contrast injection was performed only if indicated. Patients
who required sphincterotomy or other therapeutic procedures
based on the findings of cholangiopancreatography were
randomised into one of two groups: (1) the somatostatin
group received an intravenous bolus injection of 250 mg
somatostatin (Somatostatin-UCB; UCB Pharma, Brussels,
Belgium) immediately after the diagnostic cholangiopancrea-
tography but before sphincterotomy or other therapeutic
procedures in the same session; (2) the placebo group
received a bolus of the same volume of intravenous normal
saline immediately after the diagnostic cholangiopancreato-
graphy. Therapeutic procedures in this study included
sphincterotomy, pre-cut papillotomy, stenting, stone extrac-
tion, or balloon dilatation of the sphincter of Oddi. Only
patients requiring a therapeutic procedure were included in
the study.
Randomisation was carried out only after the diagnostic
cholangiopancreatography was obtained and the need for
therapeutic interventions was decided. Randomisation was
performed by a nurse, who was not involved in the procedure
or any part of patient care, by opening numbered sealed
envelopes containing computer generated random numbers
assigning patients to the somatostatin or placebo group
without stratification. The sealed envelopes and drugs were
kept in the endoscopy suite. Somatostatin or placebo
injection was given by the same nurse who performed the
randomisation. The endoscopist, the nurse assisting the
procedure, and the patient were all blind to the treatment
allocation. The therapeutic procedure was then performed
after the injection was given. Sphincterotomy was performed
using pure cut current with an output power of 30 W.
The endoscopists completed a data collection sheet
immediately after finishing the therapeutic procedure. CBD
cannulation was rated by the endoscopists as ‘‘easy’’ or
‘‘difficult’’ (requiring three or more attempts to achieve deep
cannulation of the CBD). Details of the endoscopic findings
and procedures were recorded.
After ERCP, all patients were fasted for at least six hours
and stayed overnight for 24 hours, as is the policy of our
institution. Serum amylase was measured before ERCP
(baseline) and at six and 24 hours afterwards. Clinical
parameters including abdominal pain, tenderness, and
requirement for analgesia (intramuscular meperidine) were
documented during the 24 hours after the procedure by the
physicians in the ward, who were not aware of whether the
patient had received somatostatin or placebo during ERCP.
All other ERCP related complications were noted. For
patients who developed post-ERCP pancreatitis, serum
amylase was monitored daily until it returned to normal.
Patients continued to fast in the hospital until amylase levels
returned to normal and pain subsided.
Study outcomes
The primary outcome of the study was the incidence of post-
ERCP clinical pancreatitis, which is defined as new or
worsened abdominal pain and tenderness persisting for more
than 24 hours after endoscopy with a raised serum amylase
level more than three times the upper normal limit (110 IU/l)
at 24 hours.6 17 Severity of pancreatitis was classified as mild
when the length of stay was (3 nights, moderate when
hospital stay was 4–10 nights, and severe if more than
10 days of hospitalisation, intensive care unit admission, or
surgery was needed for pancreatitis.17 For patients who
required further hospital stay for other reasons after
resolution of post-ERCP pancreatitis, the number of days
from the date of ERCP until the date of resolution of
abdominal pain and normalisation of serum amylase levels
was taken as hospital stay due to pancreatitis. A secondary
outcome was the incidence of hyperamylasemia, which was
defined as an elevation in serum amylase levels to greater
than three times the upper normal limit at either six or
24 hours after ERCP.
Statistical analysis
Based on previous studies,6 7 it was estimated that the
incidence of post-ERCP pancreatitis after endoscopic sphinc-
terotomy or therapeutic ERCP procedures in the placebo
group would be approximately 15%. Sample size calculations
showed that 130 patients in each group were needed for an a
error of 0.05 and a b error of 0.20, based on the assumption
that somatostatin could reduce the incidence of pancreatitis
from 15% to 5%.
The x2 test (or Fisher’s exact test where appropriate) was
used for comparison of categorical data. All continuous data
were expressed as median with interquartile range and
compared using the Mann-Whitney U test. A p value ,0.05
was considered statistically significant. All analyses were
performed using statistical software (SPSS 9.0; SPSS, Inc,
Chicago, Illinois, USA).
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RESULTS
Over a period of 24 months from July 2000 to June 2002, 270
patients were randomised, with 135 patients in each of the
treatment arms (fig 1). Data were complete except in three
patients who had either the six hour (n = 2) or 24 hour
(n = 1) post-ERCP serum amylase level not checked. These
three patients were included in the analysis.
Clinical and endoscopic data
The two groups were comparable in terms of age, sex,
incidence of previous pancreatitis, and indications for
therapeutic ERCP (table 1). The most common indication
for therapeutic ERCP was CBD stone. Therapeutic man-
oeuvres and endoscopic observations are shown in table 2.
Overall, 190 of 270 patients (70.4%) had endoscopic
sphincterotomies, all of which were biliary sphincterotomies.
There were no significant differences between the two groups
in the proportion of patients requiring endoscopic sphinctero-
tomy or other therapeutic procedures. The two groups also
had similar proportions of patients with non-dilated bile
duct, difficult CBD cannulation, repeated pancreatic duct
injection, and pancreatic acinarisation, which were endo-
scopic observations that might influence the incidence of
pancreatitis.
Post-ERCP serum amylase levels
There was no significant difference in pre-ERCP serum
amylase levels between the two groups (median 69 (53–86)
v 72 (56–88) IU/l; p = 0.433). However, both the six hour
post-ERCP serum amylase level (median 135 (74–358) v 210
(87–679) IU/l; p = 0.028) and the 24 hour post-ERCP serum
862 patients undergoing diagnostic
± therapeutic ERCP
282 patients eligible for study
270 patients randomised
135 patients received
somatostatin
135 patients received
placebo
Figure 1 Trial profile. ERCP, endoscopic retrograde
cholangiopancreatography.
Table 1 Demographic data and indications for therapeutic endoscopic retrograde
cholangiopancreatography
Somatostatin group (n = 135) Placebo group (n = 135)
Sex (M/F) 65/70 72/63
Age (y) 69 (56–76) 67 (52–75)
Previous pancreatitis 8 (5.9%) 6 (4.4%)
Diagnosis
CBD stone 94 (69.6%) 94 (69.6%)
Intrahepatic ductal stone 12 (8.9%) 10 (7.4%)
Carcinoma of pancreas 10 (7.4%) 12 (8.9%)
Carcinoma of CBD 6 (4.4%) 6 (4.4%)
Carcinoma of ampulla 4 (3.0%) 3 (2.2%)
Klatskin tumour 5 (3.7%) 6 (4.4%)
Hepatocellular carcinoma 2 (1.5%) 2 (1.5%)
Pancreatic cystoadenoma 0 (0%) 1 (0.7%)
Choledochal cyst 1 (0.7%) 0 (0%)
Post-cholecystectomy bile leakage 1 (0.7%) 1 (0.7%)
Age is expressed as median (interquartile range). All other values are number (%).
CBD, common bile duct.
There were no significant differences between the two groups.
Table 2 Therapeutic procedures and other endoscopic findings
Somatostatin group
(n = 135)
Placebo group
(n = 135) p Value
Therapeutic procedure*
Biliary sphincterotomy 98 (72.6%) 92 (68.1%) 0.424
Precut 6 (4.4%) 5 (3.7%) 0.758
Biliary stenting 47 (34.8%) 54 (40.0%) 0.379
CBD stone extraction 62 (45.9%) 51 (37.8%) 0.175
Balloon dilation of sphincter of
Oddi 7 (5.2%) 6 (4.4%) 0.776
Difficult cannulation 58 (43.0%) 56 (41.5%) 0.805
Non-dilated CBD 44 (32.6%) 46 (34.1%) 0.796
Pancreatic duct cannulation 38 (28.1%) 42 (31.1%) 0.594
Repeated (>3 times) pancreatic
injection 7 (5.2%) 6 (4.4%) 0.776
Pancreatic acinarisation 3 (2.2%) 4 (3.0%) 1.000
Values are number (%).
CBD, common bile duct.
*All patients had at least one therapeutic procedure; some patients had more than one procedure.
Required more than three attempts at cannulation.
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amylase level (median 128 (2–237) v 182 (6–605) IU/l;
p = 0.007) were significantly lower in the somatostatin group
than in the placebo group. Hyperamylasemia was observed
less frequently in the somatostatin group than in the placebo
group (p = 0.036, table 3).
Post-ERCP clinical pancreatit is
Sixteen patients (12.0%) in the somatostatin group and 27
patients (20.0%) in the placebo group developed abdominal
pain (or worsening of abdominal pain) after ERCP
(p = 0.067, table 3). The incidence of clinical pancreatitis
was significantly lower in the somatostatin group compared
with the placebo group (4.4% v 13.3%; p = 0.010). Based on
our results, 11 patients need to be treated with somatostatin
to prevent one case of post-ERCP pancreatitis. There were no
significant differences in the frequencies of pancreatitis
between patients who had undergone sphincterotomy and
those who had a therapeutic procedure without sphinctero-
tomy within the somatostatin group (4.1% v 5.4%; p = 0.666)
or the placebo group (13.0% v 14.0%; p = 0.885).
Three patients in the somatostatin group and nine patients
in the placebo group had moderate pancreatitis; the others
had mild pancreatitis. None of these patients required
intensive care unit admission or surgical intervention. The
median duration of post-ERCP hospital stay in the somato-
statin and placebo groups was 2 (1–3) and 3 (1–4) days,
respectively (p = 0.048). More specifically, the total extra
hospital stay due to post-ERCP pancreatitis in the somato-
statin and placebo groups was 48 and 94 days, respectively.
Use of somatostatin resulted in a reduction of 0.34 days of
hospital stay per patient treated.
In addition to post-ERCP pancreatitis, post-sphincterotomy
bleeding requiring endoscopic haemostasis occurred in two
patients in each group, respectively. One patient in the
somatostatin group had post-sphincterotomy duodenal per-
foration that was managed conservatively, and one patient in
the placebo group developed acute cholangitis after ERCP.
There were no deaths related to ERCP. No adverse effect
attributable to somatostatin was observed.
DISCUSSION
Despite the technical improvements in recent years and the
increased expertise of operators, the incidence of pancreatitis
after ERCP and endoscopic sphincterotomy has not
decreased.22 The search for an effective prophylactic therapy
for post-ERCP pancreatitis is important. Studies on ster-
oids,3 4 allopurinol,4 and nifedipine5 have yielded disappoint-
ing results. Currently, somatostatin and gabexate appear to
be agents that may be effective in preventing post-ERCP
pancreatitis.6 7 10 11 Both somatostatin and octreotide are
potent inhibitors of exocrine pancreatic secretion. However,
unlike somatostatin, octreotide has not been found to reduce
post-ERCP pancreatitis.8 9 The exact reason for the different
effects of somatostatin and octreotide remains unclear.23 One
possible explanation might be that octreotide increases the
basal pressure of the sphincter of Oddi24 whereas somato-
statin inhibits sphincter contraction.25 Octreotide is usually
given at doses of 0.1 mg or 0.2 mg by subcutaneous injection
before ERCP, and it has been suggested that the dosage used
might not have an effect on pancreatic enzyme secretion.9 11 A
recent randomised study suggested that interleukin 10,
which is a potent anti-inflammatory cytokine, may reduce
the incidence of pancreatitis after therapeutic ERCP.26
However, another trial found that interleukin 10 was not
effective.27
The ideal pharmacological prevention of post-ERCP pan-
creatitis should meet the following three criteria: (1) effective
in patients who really risk developing post-ERCP pancreatitis;
(2) not require prolonged administration in the post-
procedure period; and (3) be as economical as possible to
make it cost effective. Of the currently available drugs that
may be useful, somatostatin is the least expensive. Although
early randomised trials failed to demonstrate a significant
benefit of somatostatin,12 14 the sample size in these trials
with fewer than 30 patients in each arm was not adequate.
Our previous study involving 220 patients showed that
continuous infusion of somatostatin for 12 hours after
ERCP was effective in reducing post-ERCP pancreatitis.6
Another group, in a study of 160 patients, demonstrated
that intravenous bolus somatostatin before ERCP reduced
post-ERCP pancreatitis, especially after sphincterotomy.7
Intravenous bolus injection is a less costly way of adminis-
tering somatostatin, but the use of somatostatin for all
patients undergoing ERCP may not be cost effective, even
with bolus injection.7
In the current trial, we demonstrated that an intravenous
bolus injection of somatostatin after diagnostic cholangio-
pancreatography reduced the incidence of post-ERCP hyper-
amylasemia and pancreatitis in selected patients undergoing
sphincterotomy or other therapeutic procedures. There was
also a trend towards reduced frequency of abdominal pain in
the somatostatin group, although this was not significantly
different from the placebo group. The reduced incidence of
post-ERCP abdominal pain was mainly due to the decrease in
the frequency of pancreatitis, as the number of patients with
abdominal pain not related to pancreatitis was similar
between the two groups (10 and nine patients, respectively).
In all of the previous trials on pharmacological prevention of
post-ERCP pancreatitis, the prophylactic agent was given
before ERCP, which did not allow selective use of the agent in
high risk patients, except in those with known risk factors.
This is a major drawback that has limited the clinical
application of any drug for prophylaxis of post-ERCP
pancreatitis because the main risk factors for post-ERCP
pancreatitis were related to the procedure, and hence the risk
of pancreatitis could only be predicted after diagnostic
cholangiopancreatography. Our novel approach of selective
use of somatostatin for high risk patients after diagnostic
Table 3 Incidence of post-endoscopic retrograde cholangiopancreatography
hyperamylasemia, abdominal pain, and clinical pancreatitis
Somatostatin group
(n = 135)
Placebo group
(n = 135) p Value
Hyperamylasemia 35 (26.0%) 52 (38.5%) 0.036
Abdominal pain 16 (12.0%) 27 (20.0%) 0.067
Clinical pancreatitis
All 6 (4.4%) 18 (13.3%) 0.010
Mild 3 9
Moderate 3 9
Severe 0 0
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cholangiopancreatography allows the most cost effective use
of the drug to prevent post-ERCP pancreatitis.
In accordance with the findings of other studies,6 7 9 most
cases of post-ERCP pancreatitis in this study were mild.
Mortality from post-ERCP pancreatitis is rare. The main
consequence of this complication is prolonged hospital stay.
Hence it is important to consider the reduction in hospital
stay for pancreatitis using prophylactic somatostatin versus
the cost of the therapy. This has not been evaluated in
previous studies. In this study, somatostatin resulted in an
average reduction of 0.34 days of hospital stay per patient
treated. In our institution, the cost of one dose of
somatostatin was US$15.00, whereas the average cost of
0.34 days of extra hospital stay is US$130.00 per patient.
Hence the use of prophylactic somatostatin in the setting of
this trial was cost effective. The cost-benefit ratio will be
further improved if the loss of working days of patients
suffering from post-ERCP pancreatitis is taken into account.
Our approach of administering somatostatin has a major
advantage of being applicable to outpatient or day case ERCP
practice, which is the current trend of practice even for
therapeutic ERCP procedures.15
In this study, we chose patients undergoing endoscopic
sphincterotomy or other therapeutic procedures as study
subjects. Previous studies have shown that such patients are
at a higher risk of post-PRCP pancreatitis than those
undergoing diagnostic ERCP alone, presumably because of
the thermal or mechanical injury to papilla and pancreatic
orifice.2 17 18 20 Although one recent study found that biliary
sphincterotomy was not an independent risk factor for post-
ERCP pancreatitis,28 other studies have demonstrated a
higher frequency of post-ERCP pancreatitis associated with
biliary sphincterotomy.2 6 20 The relatively high incidence of
post-ERCP pancreatitis in our placebo group (13.3%)
probably reflected prospective data collection. Other recent
prospective studies have reported even higher frequencies of
post-ERCP pancreatitis (18–24%) in the placebo group after
sphincterotomy or other therapeutic procedures.7 26 In addi-
tion to sphincterotomy and therapeutic procedures, patient
factors such as the size of the CBD and other technical factors
such as difficult CBD cannulation, could also affect the risk of
post-ERCP pancreatitis. However, given that the frequencies
of such endoscopic observations were similar between the
two groups, it is unlikely that there was significant bias
related to these factors.
It is possible that some degree of pancreatic injury might
have already been incurred while obtaining a cholangiopan-
creatography before sphincterotomy or other therapeutic
procedures. A delay of a few hours typically exists between
the pancreatic injury and the peak of hyperamylasemia or
onset of symptoms in post-ERCP pancreatitis.29 This provides
a ‘‘therapeutic window’’ for drugs to work after initiation of
the pancreatic injury. Coupled with the rapid onset of action
of bolus intravenous somatostatin, this may explain the
efficacy of the drug in reducing the incidence of pancreatitis
even when it was given after instead of before diagnostic
cholangiopancreatography. In addition to its effect on
pancreatic enzyme secretion, recent evidence suggested that
somatostatin could reduce the inflammatory reaction of
acute pancreatitis through modulation of the cytokine
cascade and induction of apoptosis in pancreatic acinar
cells.30 31 This anti-inflammatory effect of somatostatin may
be another mechanism for its efficacy in preventing post-
ERCP pancreatitis when given as a bolus injection after
diagnostic ERCP. A recent meta-analysis of clinical trials
suggested that somatostatin could reduce the mortality of
severe acute pancreatitis.32 The use of somatostatin at the
initial onset of pancreatic inflammation appears to be a
rational approach to prevent post-ERCP pancreatitis.
In this trial, we confined the study to patients undergoing
therapeutic procedures, and most of the therapeutic proce-
dures were performed for biliary diseases. The results cannot
be generalised to other situations that predispose to post-
ERCP pancreatitis. Repeated pancreatic duct injection,
pancreatic acinarisation, and pancreatic therapeutic proce-
dures were also risk factors for post-ERCP pancreatitis that
were unpredictable before ERCP.21 28 The use of somatostatin
in such circumstances warrants further investigation.
In conclusion, this study shows that a single dose of
intravenous bolus somatostatin given immediately after
diagnostic cholangiopancreatography can decrease the inci-
dence of pancreatitis after sphincterotomy or other thera-
peutic ERCP procedures. Our study provides insight into a
new direction for future research on a more cost effective
approach of using pharmacological agents to prevent post-
ERCP pancreatitis. The use of the cheapest drug available,
administered in the least costly way to a selected high risk
group of patients, as demonstrated in this study, may offer
the real possibility of cost effective prophylaxis of post-ERCP
pancreatitis.
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GI SNAPSHOT
Answer
From question on page 1727
This contrast enhanced computed tomography image shows a large mass within the right
lobe of the liver, measuring 17613 cm. Because of the peripheral enhancement of the mass,
and the central filling seen on delayed images, this finding was most consistent with giant
haemangioma. This presumptive diagnosis was confirmed by a nuclear medicine red blood
cell scan. After other infectious causes were ruled out, the patient’s fever was felt to be due to
this mass. The patient underwent a right hepatic lobectomy, which he tolerated well. His fevers
resolved from postoperative day 3 onwards. He was discharged on postoperative day 8 and
remained asymptomatic at his follow up appointments in clinic for two months. The final
pathological diagnosis and cause of this patient’s fever of unknown origin was a giant
haemangioma with foci of thrombosis and infarction.
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